期刊
CHEMISTRY & BIOLOGY
卷 19, 期 9, 页码 1080-1082出版社
CELL PRESS
DOI: 10.1016/j.chembiol.2012.09.002
关键词
-
资金
- NHLBI NIH HHS [HL89934, HL70694, R01 HL089934, P01 HL070694, R37 HL067330, HL67330, R01 HL067330] Funding Source: Medline
Sphingosine 1-phosphate receptor-1 (S1P(1)), a novel therapeutic target for multiple sclerosis, regulates lymphocyte trafficking, heart rate, and vascular function. The discovery of NIBR-0213, a competitive antagonist for S1P(1) that inhibits autoimmune inflammation while sparing bradycardia (Quancard et al., in this issue of Chemistry & Biology), suggests that fine-tuning of SIP, modulators may lead to novel immune modulators with better efficacy to adverse events ratio.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据